Cancer Research Funding, CancerLinQ, Superbug Treatment, ADHD Drugs, Big Pharma, Medicaid Growth, and the Opioid Crisis
In this week’s BioBlog we look at recent developments across the healthcare field, including cancer research funding and data tracking of cancer treatments, a revamped antibiotic to combat superbugs, ADHD medication, Big Pharma, Medicaid enrollment, and the opioid crisis.
Looking ahead to significant proposed cuts to the National Institutes of Health budget and lagging increases in previous years when compared to inflation, it seems that the US is falling behind on cancer research.
In an effort to better track the use of cancer treatments CancerLinQ has formed a long term partnership with the FDA to track the use of the treatments for a better understanding of outcomes and quality of care.
Scientists have re-engineered the antibiotic Vanomyacin in order to help combat the superbug VRE.
For many years there has been little done to develop new ADHD medications with other compounds, but that could soon change as the push for an anti-stimulant alternative increases.
In recent years, Big Pharma has shifted it’s main focus to new areas such as investing in digital health.
The new AIS survey shows that enrollment has increased in Medicaid Managed Care plans in many states as well as seeing growth in the Fee for Service option. This is largely due to increased eligibility.
HHS Offers Grants to Tackle Opioid Crisis, While NIH Outlines Short-Term and Long-Term Goals to Address Addiction Epidemic
The Department of Health and Human services has announced they will make $70 million in grants available to help the current opioid addiction crisis.